Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research Programme: Hematopoietic progenitor kinase 1 inhibitors - Cullinan Therapeutics

Next Previous
X
Search
Drug Profile

Research Programme: Hematopoietic progenitor kinase 1 inhibitors - Cullinan Therapeutics

Latest Information Update: 23 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cullinan Oncology
  • Developer Cullinan Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Hematopoietic progenitor kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Apr 2024 Cullinan Oncology is now called Cullinan Therapeutics
  • 12 May 2023 Preclinical trials in Cancer in USA (PO) before May 2023
  • 12 May 2023 Cullinan Oncology and Icahn School of Medicine at Mount Sinai jointly own one patent family related to compositions comprising compounds which degrade HPK1 and methods of using such compounds therapeutically

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top